Navigation Links
VIRxSYS Presents Data on HIV Vaccine at Keystone HIV Vaccine Symposia
Date:3/28/2008

HIV-Based Lentiviral vector VRX1023 Shows Promising Results

GAITHERSBURG, Md., March 28 /PRNewswire/ -- VIRxSYS Corporation will present initial scientific data for VRX1023 today at the Keystone Symposia Conference in Banff, Alberta. VRX1023 is part of a new vaccine approach -- using HIV-based lentivector as vector boost. VRX1023, an HIV antigen expressing lentiviral vector, has produced positive results in mice and in preliminary non-human primate studies. A larger, confirmatory study in Rhesus Macaques has been initiated.

"VRX1023 shows exciting promise," says Dr. Franck Lemiale, Director of Research and Development, Immunobiology for VIRxSYS. "The results from these mouse studies are very encouraging. We have seen significant long term response against HIV proteins both in terms of cellular immunity, which is mediated by T Lymphocytes, and humoral immunity, which is mediated by antibodies."

VIRxSYS takes a different approach as anti-HIV vaccine than recently publicized failed vaccines. The company is using an engineered HIV-based lentiviral vector to deliver the vaccinating antigens. In small animals, the VRX1023 lentivector has induced long-lasting cellular and humoral response against HIV. Using a DNA prime/vector boost strategy, VIRxSYS has obtained with VRX1023 greater anti-HIV immune responses than with other viral vector boost approaches currently used in the clinic, including adenoviral vectors similar to those that have been extensively tested in patients.

The ultimate goal for an anti-HIV vaccine is to suppress the impact of the initial infection, thereby significantly slowing the process of the disease. Due to the properties of the virus, a traditional total sterilizing goal may not be achievable for an anti-HIV vaccine. The next step would be to a prophylactic vaccine, which would reduce the impact of hyper-viremia in the first weeks of the infection. The aim of this vaccine is to suppress initial viremia, preventing the massive destruction of CD4 T cells, and also to halt the subsequent slow destruction of the immune system by the latently dormant virus. Individuals will be protected but not totally sterilized, minimizing the likelihood of new infections.

"The use of a HIV-based lentiviral vector represents a truly innovative approach to anti-HIV vaccine and to all vaccination strategies in general. With VRX1023 in particular, we are turning HIV against itself. We are exploiting the virus ability to efficiently produce proteins for vaccination purposes," said Riku Rautsola, PhD, President and CEO of VIRxSYS. "VRX1023 presents us with a renewed hope for the delivery of an anti-HIV vaccine."

About VIRxSYS

VIRxSYS is a private biotechnology company using proprietary lentiviral vector delivery and RNA payload platforms to develop therapies for serious human diseases. The Company's initial lentiviral delivery technology was exclusively licensed from The Johns Hopkins University and has been substantially advanced in the Company's laboratories. The RNA payload technology was acquired and has been integrated with the Company's lentiviral delivery technology. In addition to preclinical programs for genetic and other serious diseases, the Company is currently developing gene and vaccine therapies for HIV, one of which, VRX496, has advanced to Phase 2 human clinical trials. More information regarding VIRxSYS can be found at http://www.virxsys.com. Details for the Phase II study can be found at the NIH clinical trials website at clinicaltrials.gov/show/NCT00131560.

Contact: Jeneane Smith / Russell LaMontagne

Phone: 212.255.5340


'/>"/>
SOURCE VIRxSYS
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... -- Research and Markets has announced the addition ... report to their offering. ... The global orthopedic navigation system ... Increasing geriatric population prone to orthopedic diseases is a key ... the forecast period. Osteoarthritis and osteoporosis are most common disorders ...
(Date:3/29/2017)... Mar 29, 2017  Providence Medical Technology, Inc., ... addition of two industry veterans to the commercial ... the company to lead Global Marketing, and ... Mr. Lynch and Mr. Scott have over 40 ... Mr. Lynch joins the company with over 22 ...
(Date:3/29/2017)... 29, 2017  The leader in accelerated orthodontics, OrthoAccel ... Sam Daher , Manal Ibrahim , Kenji ... will be the featured microlecture presenters at the AcceleDent ... of Orthodontists (AAO) Annual Session, April 21-25, 2017. Orthodontists ... beginning daily at 11:20 a.m. On the opening morning ...
Breaking Medicine Technology:
(Date:3/29/2017)... , ... March 29, 2017 , ... ... webinar provides insight into the challenges employers face in trying to balance both ... managing employee benefits programs? Adding to the growing complexity, companies are finding ...
(Date:3/29/2017)... ... March 29, 2017 , ... How ... other outpatient facilities, and who are the most active developers? , In ... and Healthcare Real Estate Insights (HREI) found that outpatient medical real estate development ...
(Date:3/29/2017)... ... ... HealthCareMandA.com will host an important webinar — Home Health & Hospice: Buying, ... of the webinar will also be made available following its live presentation. The webinar ... still popular targets for healthcare investors. This highly fragmented sector bounced back in 2016, ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... have easier access to the robotic-assisted total-hip and partial-knee replacement surgeries that ... surgeons at Forbes Hospital and Jefferson Hospital recently started performing these surgeries ...
(Date:3/29/2017)... ... March 29, 2017 , ... VisualSP has helped over 1.5 million SharePoint ... option for on-premises installation of its Help System for SharePoint was at the farm ... into the entire tenant. , The company recently released a modified version of ...
Breaking Medicine News(10 mins):